Sutro Biopharma Inc expected to post a loss of 74 cents a share - Earnings Preview

Sutro Biopharma

03/11/2023 12:25

* Sutro Biopharma Inc  STRO.OQ   STRO.O  is expected to show
a
fall in quarterly revenue when it reports  results 
    * The South San Francisco California-based  company is
expected to
report  a 49.9% decrease in revenue to $12.61 million from
$25.15 million a year ago, according to the mean estimate from 9
analysts, based on LSEG data. 
    * ​Refinitiv's mean analyst estimate for Sutro Biopharma Inc
is
for a loss of 74 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Sutro
Biopharma
Inc is $17​, above​ its last closing price of $2.69. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.75       -0.73      -0.64     Beat    12.6
 Mar. 31 2023  -0.80       -0.81      -0.85     Missed  -4.8
 Dec. 31 2022  -0.61       -0.62      -0.68     Missed  -9.5​
 Sep. 30 2022  -0.75       -0.74      -0.37     Beat    49.9
 ​​Jun.        -0.43       -0.46      -0.55     Missed  -19.2
 30 2022                                                
 Mar. 31 2022  -0.77       -0.76      -0.84     Missed  -10.9​
 Dec. 31 2021  -0.70       -0.69      -0.83     Missed  -20.5
 Sep. 30 2021  -0.65       -0.65      -0.67     Missed  -2.9
 This summary was machine generated November 3 at 12:25 GMT.  All
figures in US dollars  unless otherwise stated